Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
iTeos Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference
Gosselies, Belgium - August 8, 2017 - iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announces that Michel Detheux, iTeos' Chief Executive Officer, will present a company overview at the 2017 Wedbush PacGrow Healthcare Conference on Tuesday, August 15, 2017 at 12:45 a.m. ET in New York, NY.
About iTeos Therapeutics SA
iTeos is focused on expanding the benefits of immunotherapy for cancer patients by developing a proprietary pipeline targeting A2A, immune checkpoints and non-immunogenic ("cold") tumors. It has licensed its IDO1 program, currently in Phase 1 development, to Pfizer. iTeos' competitive edge is in the combination of expertise in drug discovery, translational tumor immunology and early clinical trial design. The company uses a unique platform to identify rational combinations of immunotherapies and novel targets. Based in Gosselies, Belgium, iTeos is a spin-off from the Ludwig Cancer Research (LICR) and de Duve Institute (UCL). The company is supported in part by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development). For more information, please visit www.iteostherapeutics.com.
For further information, please contact:
Michel Detheux, CEO
iTeos therapeutics
+32 71 919 933
[email protected]
Sarah McCabe
Stern Investor Relations, Inc.
+ 1 212 362-1200
[email protected]
Amber Fennell, Mathew Neal, Hendrik Thys
Consilium Strategic Communications
+44 203 709 5700
[email protected]
